Anish Suri

Anish Suri

Company: Cue Biopharma

Job title: Chief Scientific Officer & President


Targeting IL-2 to Tumor-specific T cells via Novel Biologic Platforms: Update on CUE-101 in R/M HNSCC and Beyond 2:00 pm

To harness the fullest therapeutic potential of IL-2 immunotherapy, we have designed the CUE-100 series of Immuno-STATs (ISTs): rationally engineered Fc fusion proteins comprised of bivalent tumor-peptide-MHC (pMHC) complexes and four affinity-attenuated IL-2 molecules to preferentially engage and activate tumor-specific T cells directly in the patient Our lead clinical candidate, CUE-101, incorporates an immunodominant peptide…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.